Business Wire

Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors

ALAMEDA, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Iconic Therapeutics today announced new preclinical data that support the continued development of ...
St. Louis American

2024ASCO｜Memorial Sloan Kettering Cancer Center (MSK)’s Prof. Wungki Park Unveils Precision Targeting of TF in Pancreatic Cancer, Signaling ADC Drug Innovations

TF overexpression is associated with thrombosis, metastasis and poor prognosis in solid tumors, including cervical and pancreatic cancer. MRG004A is a novel anti-TF monoclonal antibody conjugated (ADC ...
Yahoo Finance

Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format ...
Seeking Alpha

Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal

Multitude Therapeutics out-licensed global rights (ex-Greater China) for its Tissue Factor ADC to Denmark’s Adcendo in a $1 billion agreement. Huadong Pharmaceutical acquired rights for two immune ...
FiercePharma

Lonza Group AG : Lonza enters development and manufacturing agreement with Genmab A/S

Lonza enters development and manufacturing agreement with Genmab A/S for a novel antibody drug conjugate (ADC), HuMax-TF TM • This agreement secures a development and cGMP manufacturing plan for ...
GEN

Genmab Taps into Seattle’s ADC Technology to Develop Anticancer HuMax-TF Conjugate

Firm may opt to co-develop products after Phase I trials. Seattle Genetics and Genmab shook hands on an antibody-drug conjugate (ADC) research collaboration that gives the latter rights to use Seattle ...
ascopubs.org

A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer.

GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical ...
Nasdaq

Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors

- ICON-2 is pharmacologically more potent in vivo and in vitro, with better nonclinical tolerability, compared with a monomethyl auristatin E (MMAE) anti-TF antibody-drug conjugate (ADC) - - Data ...
MarketWatch

2024ASCO Memorial Sloan Kettering Cancer Center (MSK)'s Prof. Wungki Park Unveils Precision Targeting of TF in Pancreatic Cancer, Signaling ADC Drug Innovations

CHICAGO, June 12, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 31 to June 4, shone a spotlight on MRG004A, a novel antibody-drug ...
KTLA

2024ASCO｜Memorial Sloan Kettering Cancer Center (MSK)'s Prof. Wungki Park Unveils Precision Targeting of TF in Pancreatic Cancer, Signaling ADC Drug Innovations

TF overexpression is associated with thrombosis, metastasis and poor prognosis in solid tumors, including cervical and pancreatic cancer. MRG004A is a novel anti-TF monoclonal antibody conjugated (ADC ...